
CPAY · NYSE
The evidence points to a Buy consensus, but the analyst count is inconsistent: Public.com reports 12 analysts, while another supplied report cites 11 Buys and three Holds; the supplied consensus line says Buy across zero analysts and gives a $475 mean target. Recent named target revisions cluster from KBW’s $525 to Cantor Fitzgerald’s $550, a $25 spread, with Scotiabank at $539. Cantor is most bullish among these revisions and KBW least bullish. All three raised targets over the period, with no supplied evidence of a downward revision. The reports cite strong quarterly results and higher guidance, but do not explain the valuation assumptions behind the target differences.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Cantor Fitzgerald | — | $550 | +20.1% | Nov 9, 2026 | Open the report this row came from | |
| Scotiabank | — | $539 | +17.7% | Nov 5, 2026 | Open the report this row came from | |
| Keefe, Bruyette & Woods | — | $525 | +14.6% | Nov 5, 2026 | Open the report this row came from |